Published in Antimicrob Agents Chemother on October 01, 1985
Brucellosis: an overview. Emerg Infect Dis (1997) 8.28
Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas. Antimicrob Agents Chemother (1995) 1.89
Treatment of human brucellosis with doxycycline and gentamicin. Antimicrob Agents Chemother (1997) 1.70
Brucella abortus infection acquired in microbiology laboratories. J Clin Microbiol (2000) 1.31
Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis. PLoS One (2012) 1.23
Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis. Antimicrob Agents Chemother (1989) 1.22
Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis. Antimicrob Agents Chemother (1986) 1.16
Osteoarticular complications of brucellosis. Ann Rheum Dis (1991) 1.13
Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks. Antimicrob Agents Chemother (1990) 1.07
Use of rifampin in nonstaphylococcal, nonmycobacterial disease. Antimicrob Agents Chemother (1993) 0.94
Doxycycline plus streptomycin versus ciprofloxacin plus rifampicin in spinal brucellosis [ISRCTN31053647]. BMC Infect Dis (2006) 0.93
In vitro activities of new macrolides and rifapentine against Brucella spp. Antimicrob Agents Chemother (1993) 0.92
Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. Antimicrob Agents Chemother (1994) 0.92
Brucellosis in Qatar: A retrospective cohort study. Qatar Med J (2014) 0.83
Brucellosis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis (1998) 0.82
Human to human transmission of Brucella melitensis. Can J Infect Dis (1995) 0.81
Phagocytic cell function in active brucellosis. Infect Immun (1994) 0.78
Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin. Antimicrob Agents Chemother (1993) 0.76
The rose bengal plate agglutination test in the diagnosis of brucellosis. Vet Rec (1969) 2.33
The effect of antibiotics on Escherichia coli ingested by macrophages. Proc Soc Exp Biol Med (1973) 1.94
In vitro susceptibility of Brucella to various antibiotics. Appl Microbiol (1970) 1.74
Laboratory diagnosis of brucellosis in man. Bull World Health Organ (1961) 1.67
[Relation between complement fixation and incomplete antibodies (Coombs' test) in human brucellosis]. Rev Immunol Ther Antimicrob (1954) 1.46
Oxytetracycline-streptomycin therapy in brucellosis due to Brucella melitensis. AMA Arch Intern Med (1953) 1.35
Brucellosis treated with rifampicin. Arch Dis Child (1980) 1.34
Determination of the in vitro sensitivity of Brucella strains to rifampicin. Br Vet J (1976) 1.20
Rifampin in the treatment of experimental brucellosis in mice and guinea pigs. J Infect Dis (1977) 1.19
A comparative study of therapeutic agents used for treatment of acute brucellosis. Br J Clin Pract (1973) 1.17
[The treatment of brucellosis using rifampicine (author's transl)]. Nouv Presse Med (1979) 1.00
[Antibiotic treatment of brucellosis (author's transl)]. Sem Hop (1982) 0.96
[Current antimicrobial treatment of brucellosis]. Med Clin (Barc) (1983) 0.91
Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med (1995) 4.38
Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin Infect Dis (1992) 3.37
Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol (2000) 3.23
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med (1995) 3.04
Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics. J Antimicrob Chemother (1992) 2.86
Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med (1987) 2.78
Meningococcal disease in a large urban population (Barcelona, 1987-1992): predictors of dismal prognosis. Barcelona Meningococcal Disease Surveillance Group. Arch Intern Med (1999) 2.40
Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother (1998) 2.40
Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet (1999) 2.30
Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci. Am J Med (1988) 2.24
Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother (1991) 2.13
Specific antibody profile in human brucellosis. Clin Infect Dis (1992) 2.08
[Current treatment of pneumococcal meningitis]. Enferm Infecc Microbiol Clin (1991) 2.02
Characteristics of prosthetic joint infections due to Enterococcus sp. and predictors of failure: a multi-national study. Clin Microbiol Infect (2014) 2.02
Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother (1998) 2.00
Effects of antibiotics on protected specimen brush sampling in ventilator-associated pneumonia. Eur Respir J (2002) 2.00
Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis (2003) 1.92
Risk factors for nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis (1994) 1.85
Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother (1995) 1.78
Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clin Infect Dis (1996) 1.68
Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis (1995) 1.67
Streptococcal meningitis in adult patients: current epidemiology and clinical spectrum. Clin Infect Dis (1999) 1.66
Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med (1996) 1.61
Risk factors for nosocomial Legionella pneumophila pneumonia. Am J Respir Crit Care Med (1994) 1.61
Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. Clin Microbiol Infect (2014) 1.61
Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect (1997) 1.58
Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. Ann Intern Med (1992) 1.58
Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med (1995) 1.58
Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother (1996) 1.51
Infected hip hemiarthroplasties and total hip arthroplasties: Differential findings and prognosis. J Infect (2013) 1.49
Community-acquired bacteremic Pseudomonas cepacia pneumonia in an immunocompetent host. Clin Infect Dis (1992) 1.47
[Cytomegalovirus disease in patients with acquired immunodeficiency syndrome. Report of 63 cases]. Med Clin (Barc) (1993) 1.47
[Endocarditis due to penicillin-sensitive and -resistant pneumococci: the current perspectives on the disease]. Med Clin (Barc) (1993) 1.43
Efavirenz associated with corticosteroids in patients with previous severe hypersensitivity reaction due to nevirapine. AIDS (2000) 1.38
Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis (1995) 1.36
In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother (1995) 1.35
Specific antibodies detected during relapse of human brucellosis. J Infect Dis (1988) 1.33
In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis. J Antimicrob Chemother (1986) 1.32
Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis (2001) 1.30
Gram-negative bacillary cellulitis in patients with hepatic cirrhosis. Eur J Clin Microbiol Infect Dis (1994) 1.27
Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis (1995) 1.27
Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother (2002) 1.26
Pneumonia due to Legionella pneumophila and pneumococcal pneumonia: similarities and differences on presentation. Eur Respir J (1989) 1.26
Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality. J Hosp Infect (2008) 1.23
Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer. Clin Infect Dis (2000) 1.21
In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients. Antimicrob Agents Chemother (1996) 1.20
Pneumococcal peritonitis in adult patients: report of 64 cases with special reference to emergence of antibiotic resistance. Arch Intern Med (2001) 1.19
Group B streptococcal disease in nonpregnant adults: incidence, clinical characteristics, and outcome. Eur J Clin Microbiol Infect Dis (2004) 1.18
Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis (2000) 1.18
Usefulness of PCR and antigen latex agglutination test with samples obtained by transthoracic needle aspiration for diagnosis of pneumococcal pneumonia. J Clin Microbiol (1999) 1.17
Nosocomial spread of Pseudomonas aeruginosa producing the metallo-beta-lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications. Clin Microbiol Infect (2007) 1.16
Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect (2006) 1.16
Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis. Antimicrob Agents Chemother (1986) 1.16
Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med (1998) 1.14
Comparative trial of co-trimoxazole versus tetracycline-streptomycin in treating human brucellosis. J Infect Dis (1985) 1.14
Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. Antimicrob Agents Chemother (2007) 1.14
Protected bronchoalveolar lavage in the diagnosis of ventilator-associated pneumonia. Eur Respir J (1996) 1.13
Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother (2006) 1.13
Clinical evaluation of an in-house IS6110 polymerase chain reaction for diagnosis of tuberculosis. Eur J Clin Microbiol Infect Dis (2000) 1.13
Epidemiological significance of cutaneous, pharyngeal, and digestive tract colonization by multiresistant Acinetobacter baumannii in ICU patients. J Hosp Infect (1997) 1.12
High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins. Antimicrob Agents Chemother (1996) 1.11
Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob Agents Chemother (1999) 1.10
Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2010) 1.09
Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis (1999) 1.09